BIOMAT Database Logo BIOMAT Database Logo

Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. 1994

R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.

The synthetic matrix metalloproteinase inhibitor batimastat was tested for its ability to inhibit growth and metastatic spread of the B16-BL6 murine melanoma in syngeneic C57BL/6N mice. Intraperitoneal administration of batimastat resulted in a significant inhibition in the number of lung colonies produced by B16-BL6 cells injected i.v. The effect of batimastat on spontaneous metastases was examined in mice inoculated in the hind footpad with B16-BL6 melanoma. The primary tumor was removed surgically after 26-28 days. Batimastat was administered twice a day from day 14 to day 28 (pre-surgery) or from day 26 to day 44 (post-surgery). With both protocols, the median number of lung metastases was not significantly affected, but there was a significant reduction in the weight of the metastases. Finally, the effect of batimastat was examined on s.c. growth of B16-BL6 melanoma. Batimastat administered daily, starting at day of tumor transplantation, resulted in a significant growth delay, whereas treatment starting at advanced stage tumor only reduced tumor growth marginally. Our results indicate that a matrix metalloproteinase inhibitor can not only prevent the colonization of secondary organs by B16-BL6 cells but also limit the growth of solid tumors.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010649 Phenylalanine An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE. Endorphenyl,L-Phenylalanine,Phenylalanine, L-Isomer,L-Isomer Phenylalanine,Phenylalanine, L Isomer
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents.
January 2002, Anticancer research,
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Inhibition of B16-BL6 melanoma growth in mice by methionine-enkephalin.
August 1985, Journal of the National Cancer Institute,
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Growth inhibition and differentiation of murine melanoma B16-BL6 cells caused by the combination of cisplatin and caffeine.
December 1989, Japanese journal of cancer research : Gann,
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
RhoA mediates the expression of acidic extracellular pH-induced matrix metalloproteinase-9 mRNA through phospholipase D1 in mouse metastatic B16-BL6 melanoma cells.
March 2016, International journal of oncology,
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Modulation of B16-BL6 murine melanoma metastatic phenotype by tyrosine and phenylalanine restriction in the absence of host selection pressures.
January 1993, Anticancer research,
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Inhibition of growth of B16 murine malignant melanoma by exogenous interferon.
March 1980, Cancer research,
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
February 1995, Journal of the National Cancer Institute,
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Treatment with Uncaria tomentosa Promotes Apoptosis in B16-BL6 Mouse Melanoma Cells and Inhibits the Growth of B16-BL6 Tumours.
February 2021, Molecules (Basel, Switzerland),
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
[Combined effect of cisplatin and caffeine on murine B16-BL6 melanoma cells].
May 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
R G Chirivi, and A Garofalo, and M J Crimmin, and L J Bawden, and A Stoppacciaro, and P D Brown, and R Giavazzi
Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor.
January 1996, Investigative ophthalmology & visual science,
Copied contents to your clipboard!